Olmesartan/Hidroclorotiazida Alter (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil and hydrochlorothiazide, the active ingredients in Olmesartan/Hidroclorotiazida Alter, are an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic, in adult patients.

GNH USA supplies Olmesartan/Hidroclorotiazida Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/hydrochlorothiazide is used to manage hypertension by blocking the renin‑angiotensin system and promoting diuresis.

- Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Hypertension in patients with renal impairment: provides effective blood pressure control when monotherapy is insufficient. - Hypertension requiring combination therapy: offers dual action of an ARB and a thiazide diuretic for better control.

Common side effects are generally mild and related to the pharmacologic actions of the components.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Increased urination: due to the diuretic effect of hydrochlorothiazide. - Electrolyte imbalance (low potassium): may cause muscle cramps or weakness. - Fatigue: occasional tiredness during dose titration.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute renal failure: sudden loss of kidney function, especially in volume‑depleted patients. - Hyperkalemia: elevated potassium levels when combined with potassium‑sparing agents. - Angioedema: swelling of face, lips, or throat requiring emergency care. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain. - Blood dyscrasias: rare blood cell abnormalities such as agranulocytosis.

Before initiating therapy, clinicians should assess patient-specific factors and monitor relevant parameters. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Electrolyte and renal function tests: check serum potassium, sodium, creatinine, and eGFR regularly. - Pregnancy and lactation: avoid use unless clearly needed, as safety data are limited. - Concomitant potassium‑sparing drugs: use with caution to prevent hyperkalemia. - Severe hepatic impairment: dose adjustment may be required. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/hydrochlorothiazide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Lithium: may increase lithium levels, risking toxicity. - Potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - NSAIDs (especially ibuprofen): may blunt antihypertensive response and affect renal function. - Cyclosporine: can increase serum creatinine.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: blood glucose may improve, requiring dose adjustment. - Beta‑blockers: additive blood pressure lowering effect. - Calcium channel blockers: may enhance hypotensive effect. - Corticosteroids: can increase sodium retention, counteracting diuretic action. - Digoxin: monitor serum levels due to potential electrolyte shifts.